Correction: Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial–a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trial

Detalles Bibliográficos
Autores principales: Hill, Nathan R., Lasserson, Daniel, Thompson, Ben, Perera-Salazar, Rafael, Wolstenholme, Jane, Bower, Peter, Blakeman, Thomas, Fitzmaurice, David, Little, Paul, Feder, Gene, Qureshi, Nadeem, Taal, Maarten, Townend, Jonathan, Ferro, Charles, McManus, Richard, Hobbs, F. D. Richard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Correction
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9743765/
https://www.ncbi.nlm.nih.gov/pubmed/36510220
http://dx.doi.org/10.1186/s13063-022-06972-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9743765/
https://www.ncbi.nlm.nih.gov/pubmed/36510220
http://dx.doi.org/10.1186/s13063-022-06972-9

Ejemplares similares